Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) just unveiled an update.
Jiangsu Recbio Technology Co., Ltd. announced the acceptance of its application for a clinical trial of its new HPV 9-valent vaccine, REC604c, by the National Medical Products Administration in China. The REC604c vaccine, enhanced with a novel adjuvant developed in-house, seeks to reduce vaccination doses while boosting immunogenicity and cross-protection. This development targets the male market, acknowledging the global trend of including adolescent males in HPV vaccination programs. The potential market in China is significant, with over 300 million eligible males, but success is not guaranteed.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a biotechnology company based in China, focusing on the development of innovative vaccines. The company specializes in recombinant vaccines, targeting markets for various age groups and genders.
YTD Price Performance: -8.63%
Average Trading Volume: 31,379
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$3.96B
Find detailed analytics on 2179 stock on TipRanks’ Stock Analysis page.